{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T03:57:57Z","timestamp":1773374277546,"version":"3.50.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,3,22]],"date-time":"2018-03-22T00:00:00Z","timestamp":1521676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,3,22]],"date-time":"2018-03-22T00:00:00Z","timestamp":1521676800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>A novel blood-borne virus called the human hepegivirus 1 (HHpgV-1) was recently discovered in hemophilia patients. The present study aimed to investigate the presence of HHpgV-1 in hemophilia patients. A total of 436 serum samples were investigated for the presence of hepatitis C virus (HCV), human pegivirus-1 (HPgV-1), torque teno virus (TTV), and HHpgV-1. Out of the 436 patients, 163 (37.4%), 19 (4.4%), 76 (17.4%), and four (0.9%) patients were positive for HCV, HPgV-1, TTV, and HHpgV-1, respectively. HHpgV-1 patients had a mean viral load of 4.9\u2009\u00b1\u20090.3 log RNA copies\/mL and were co-infected with HCV-1a, HPgV-1, and TTV. Moreover, three HHpgV-1-positive patients exhibited stage F0 liver fibrosis. HCV viral load in HHpgV-1-positive patients was lower than those of HHpgV-1-negative patients. Results also revealed that co-infection of HHpgV-1 with HPgV-1 and HCV may play a protective role in patients with chronic HCV. In conclusion, we detected a low frequency of HHpgV-1 infection in hemophilia patients, and results suggested that HHpgV-1 infection was correlated with the presence of other blood-borne viruses and is likely to also correlate with low HCV viral load and reduced severity of liver disease. Additional studies are required to further investigate the clinical importance of HHpgV-1.<\/jats:p>","DOI":"10.1038\/s41598-018-23490-4","type":"journal-article","created":{"date-parts":[[2018,3,29]],"date-time":"2018-03-29T01:42:00Z","timestamp":1522287720000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["First detection of human hepegivirus-1 (HHpgV-1) in Iranian patients with hemophilia"],"prefix":"10.1038","volume":"8","author":[{"given":"Yazdan","family":"Bijvand","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad Reza","family":"Aghasadeghi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatemeh","family":"Sakhaee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parviz","family":"Pakzad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farzam","family":"Vaziri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alireza Azizi","family":"Saraji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatemeh Rahimi","family":"Jamnani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seyed Davar","family":"Siadat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abolfazl","family":"Fateh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,3,22]]},"reference":[{"key":"23490_CR1","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.blre.2015.07.004","volume":"30","author":"G Di Minno","year":"2016","unstructured":"Di Minno, G. et al. Current concepts in the prevention of pathogen transmission via blood\/plasma-derived products for bleeding disorders. Blood Rev 30, 35\u201348 (2016).","journal-title":"Blood Rev"},{"key":"23490_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-7-24","volume":"7","author":"M Franchini","year":"2012","unstructured":"Franchini, M. & Mannucci, P. M. Past, present and future of hemophilia: a narrative review. Orphanet J Rare Dis 7, 24 (2012).","journal-title":"Orphanet J Rare Dis"},{"key":"23490_CR3","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1111\/j.1538-7836.2006.01808.x","volume":"4","author":"I Plug","year":"2006","unstructured":"Plug, I. et al. Mortality and causes of death in patients with hemophilia, 1992\u20132001: a prospective cohort study. J Thromb Haemost 4, 510\u2013516 (2006).","journal-title":"J Thromb Haemost"},{"key":"23490_CR4","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1111\/trf.12371","volume":"53","author":"SL Stramer","year":"2013","unstructured":"Stramer, S. L. & Dodd, R. Y. Transfusion\u2010transmitted emerging infectious diseases: 30 years of challenges and progress. Transfusion 53, 2375\u20132383 (2013).","journal-title":"Transfusion"},{"key":"23490_CR5","doi-asserted-by":"publisher","first-page":"e01466","DOI":"10.1128\/mBio.01466-15","volume":"6","author":"A Kapoor","year":"2015","unstructured":"Kapoor, A. et al. Virome analysis of transfusion recipients reveals a novel human virus that shares genomic features with hepaciviruses and pegiviruses. MBio 6, e01466\u201301415 (2015).","journal-title":"MBio"},{"key":"23490_CR6","doi-asserted-by":"crossref","unstructured":"Kalantari, H., Hoseini, H., Babak, A. & Yaran, M. Validation of hepascore as a predictor of liver fibrosis in patients with chronic hepatitis C infection. Hepat Res Treat 2011 (2011).","DOI":"10.1155\/2011\/972759"},{"key":"23490_CR7","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/S0928-0197(96)00242-5","volume":"7","author":"P Pohjanpelto","year":"1996","unstructured":"Pohjanpelto, P., Lappalainen, M., Widell, A., Asikainen, K. & Paunio, M. Hepatitis C genotypes in Finland determined by RFLP. Clin Diagn Virol 7, 7\u201316 (1996).","journal-title":"Clin Diagn Virol"},{"key":"23490_CR8","first-page":"29","volume":"3","author":"A Fateh","year":"2009","unstructured":"Fateh, A. et al. Study on Prevalence of TTV among Cirrhotic patients due to Hepatitis B & C in Ahwaz University Hospitals during the Years 2004\u20132005. Iran J Virol 3, 29\u201333 (2009).","journal-title":"Iran J Virol"},{"key":"23490_CR9","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/S0042-6822(03)00585-3","volume":"316","author":"SL George","year":"2003","unstructured":"George, S. L., Xiang, J. & Stapleton, J. T. Clinical isolates of GB virus type C vary in their ability to persist and replicate in peripheral blood mononuclear cell cultures. Virology 316, 191\u2013201 (2003).","journal-title":"Virology"},{"key":"23490_CR10","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.3851\/IMP2309","volume":"17","author":"RT Rydze","year":"2012","unstructured":"Rydze, R. T., Bhattarai, N. & Stapleton, J. T. GB virus C infection is associated with a reduced rate of reactivation of latent HIV and protection against activation-induced T-cell death. Antivir Ther 17, 1271 (2012).","journal-title":"Antivir Ther"},{"key":"23490_CR11","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1128\/JCM.00515-16","volume":"54","author":"KE Coller","year":"2016","unstructured":"Coller, K. E. et al. Antibodies to the Novel Human Pegivirus 2 Are Associated with Active and Resolved Infections. J Clin Microbiol 54, 2023\u20132030 (2016).","journal-title":"J Clin Microbiol"},{"key":"23490_CR12","doi-asserted-by":"publisher","first-page":"2725","DOI":"10.1093\/molbev\/mst197","volume":"30","author":"K Tamura","year":"2013","unstructured":"Tamura, K., Stecher, G., Peterson, D., Filipski, A. & Kumar, S. MEGA6: molecular evolutionary genetics analysis version 6.0. Mol Biol Evol 30, 2725\u20132729 (2013).","journal-title":"Mol Biol Evol"},{"key":"23490_CR13","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1093\/cid\/cix748","volume":"66","author":"H Wang","year":"2018","unstructured":"Wang, H. et al. A Novel Human Pegivirus, HPgV-2 (HHpgV-1), Is Tightly Associated With Hepatitis C Virus (HCV) Infection and HCV\/Human Immunodeficiency Virus Type 1 Coinfection. Clin Infect Dis 66, 29\u201335 (2018).","journal-title":"Clin Infect Dis"},{"key":"23490_CR14","doi-asserted-by":"publisher","first-page":"671","DOI":"10.3201\/eid2204.151812","volume":"22","author":"D Bonsall","year":"2016","unstructured":"Bonsall, D. et al. Evaluation of viremia frequencies of a novel human pegivirus by using bioinformatic screening and PCR. Emerg Infect Dis 22, 671 (2016).","journal-title":"Emerg Infect Dis"},{"key":"23490_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7326\/M17-0085","volume":"167","author":"AJ Kandathil","year":"2017","unstructured":"Kandathil, A. J. et al. Presence of Human Hepegivirus-1 in a Cohort of People Who Inject Drugs. Ann Intern Med 167, 1\u20137 (2017).","journal-title":"Ann Intern Med"},{"key":"23490_CR16","first-page":"180","volume":"48","author":"ML Cuestas","year":"2016","unstructured":"Cuestas, M. L. New virus discovered in blood supply: Human hepegivirus-1 (HHpgV-1). Rev Argent Microbiol 48, 180\u2013181 (2016).","journal-title":"Rev Argent Microbiol"},{"key":"23490_CR17","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/gene.2017.12","volume":"18","author":"M Asnavandi","year":"2017","unstructured":"Asnavandi, M. et al. EGFR rs11506105 and IFNL3 SNPs but not rs8099917 are strongly associated with treatment responses in Iranian patients with chronic hepatitis C. Genes Immun 18, 144\u2013151 (2017).","journal-title":"Genes Immun"},{"key":"23490_CR18","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.meegid.2017.07.023","volume":"54","author":"F Sakhaee","year":"2017","unstructured":"Sakhaee, F. et al. The impact of genetic variation in IL28B, IFNL4 and HLA genes on treatment responses against chronic hepatitis C virus infection. Infect Genet Evol 54, 330\u2013337 (2017).","journal-title":"Infect Genet Evol"},{"key":"23490_CR19","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.phrp.2015.11.004","volume":"7","author":"A Fateh","year":"2016","unstructured":"Fateh, A. et al. Comparison of three different methods for detection of il28 rs12979860 polymorphisms as a predictor of treatment outcome in patients with hepatitis C virus. Osong Public Health Res Perspect 7, 83\u201389 (2016).","journal-title":"Osong Public Health Res Perspect"},{"key":"23490_CR20","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.7314\/APJCP.2015.16.5.1873","volume":"16","author":"A Fateh","year":"2015","unstructured":"Fateh, A. et al. High resolution melting curve assay for detecting rs12979860 IL28B polymorphisms involved in response of Iranian patients to chronic hepatitis C treatment. Asian Pac J Cancer Prev 16, 1873\u20131880 (2015).","journal-title":"Asian Pac J Cancer Prev"},{"key":"23490_CR21","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.gene.2017.08.005","volume":"630","author":"S Sadeghi","year":"2017","unstructured":"Sadeghi, S. et al. Effect of IL15 rs10833 and SCARB1 rs10846744 on virologic responses in chronic hepatitis C patients treated with pegylated interferon-\u03b1 and ribavirin. Gene 630, 28\u201334 (2017).","journal-title":"Gene"},{"key":"23490_CR22","unstructured":"Mushahwar, I., Erker, J., Dille, B. & Desai, S. Recently discovered blood-borne viruses. In: Forum (Genoa, Italy). 98\u2013122 (2001)."},{"key":"23490_CR23","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1111\/j.1365-2893.2009.01194.x","volume":"16","author":"EL Mohr","year":"2009","unstructured":"Mohr, E. L. & Stapleton, J. T. GB virus type C interactions with HIV: the role of envelope glycoproteins. J Viral Hepat 16, 757\u2013768 (2009).","journal-title":"J Viral Hepat"},{"key":"23490_CR24","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.tim.2012.01.004","volume":"20","author":"N Bhattarai","year":"2012","unstructured":"Bhattarai, N. & Stapleton, J. T. GB virus C: the good boy virus? Trends Microbiol 20, 124\u2013130 (2012).","journal-title":"Trends Microbiol"},{"key":"23490_CR25","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/S0166-3542(01)00172-3","volume":"52","author":"HL Tillmann","year":"2001","unstructured":"Tillmann, H. L. & Manns, M. P. GB virus-C infection in patients infected with the human immunodeficiency virus. Antiviral Res 52, 83\u201390 (2001).","journal-title":"Antiviral Res"},{"key":"23490_CR26","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1128\/JVI.02752-14","volume":"89","author":"M Lauck","year":"2015","unstructured":"Lauck, M. et al. GB virus C coinfections in West African Ebola patients. J Virol 89, 2425\u20132429 (2015).","journal-title":"J Virol"},{"key":"23490_CR27","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1111\/j.1440-1746.2009.05920.x","volume":"24","author":"MD Berzsenyi","year":"2009","unstructured":"Berzsenyi, M. D., Bowden, D. S., Roberts, S. K. & Revill, P. A. GB virus C genotype 2 predominance in a hepatitis C virus\/HIV infected population associated with reduced liver disease. J Gastroenterol Hepatol 24, 1407\u20131410 (2009).","journal-title":"J Gastroenterol Hepatol"},{"key":"23490_CR28","doi-asserted-by":"publisher","first-page":"e01767","DOI":"10.1128\/mBio.01767-15","volume":"6","author":"AL Rasmussen","year":"2015","unstructured":"Rasmussen, A. L. Probing the Viromic Frontiers. MBio 6, e01767\u201301715 (2015).","journal-title":"MBio"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-23490-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-23490-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-23490-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T03:47:18Z","timestamp":1671594438000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-23490-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,22]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["23490"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-23490-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,22]]},"assertion":[{"value":"3 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"5036"}}